GCP breaches must be met with hammer blows
This article was originally published in Scrip
Executive Summary
It is nothing short of a disgrace when a company fails to adhere to good clinical practice in a drug trial. Such disregard for regulations can result in a waste of effort, time and money, not to mention the delayed entry of a potentially important drug into world markets. Furthermore, the negative impact on the safety profile of a product hardly inspires confidence in a trial sponsor and potential marketing authorisation holder.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.